Stage 1 results from MDV3100-11: A 2-stage study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC) Meeting Abstract
| Authors: | Castan, J. C.; Schmid, P.; Awada, A.; Uppal, H.; Tudor, I. C.; Blaney, M. E.; Steinberg, J. L.; Yardley, D. A.; Hudis, C.; Traina, T. A. |
| Abstract Title: | Stage 1 results from MDV3100-11: A 2-stage study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC) |
| Meeting Title: | 7th IMPAKT Breast Cancer Conference |
| Journal Title: | Annals of Oncology |
| Volume: | 26 |
| Issue: | Suppl. 3 |
| Meeting Dates: | 2015 May 7-9 |
| Meeting Location: | Brussels, Belgium |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2015-05-01 |
| Start Page: | iii6 |
| Language: | English |
| ACCESSION: | WOS:000354890600008 |
| DOI: | 10.1093/annonc/mdv115.01 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 13P -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work